Halloween has come and gone in the US, and Americans are now gearing up for Thanksgiving and Christmas. But before the holiday season could get underway, the country went through a major political event with far-reaching implications: the midterm elections.As…
Chuikyo OKs Listing of Mounjaro, Libtayo, Imjudo; 30 Billion-Plus Peak Sales for Lilly Med
To read the full story
Related Article
- LEO Pharma’s Eczema Drug Adtralza Now Available in Japan
September 27, 2023
- Ohara’s Cancer Med Erwinase Reaches Japan Market Over 6 Years after Approval
June 15, 2023
- Lilly, Mitsubishi Tanabe Roll Out Mounjaro’s High-Dose Versions
June 13, 2023
- Lilly’s Mounjaro Hits Japan Pharmacy Shelves, Mitsubishi as Distributor
April 19, 2023
- Radicut Oral Form Now Available for ALS Patients in Japan: Mitsubishi Tanabe
April 18, 2023
- Sanofi Launches PD-1 Inhibitor Libtayo in Japan
March 31, 2023
- Xocova to Be Commercially Available from March 31
March 24, 2023
- Iron Solution MonoVer Now Available in Japan; Donepezil Patch, Cresemba to Hit Market in April
March 16, 2023
- AbbVie’s Parkinson’s Drug, Kaken’s Eschar Remover Skip March Listing
March 9, 2023
- Japan Approves Sanofi’s PD-1 Inhibitor, Teikoku’s Donepezil Tape and More
December 26, 2022
- Japan Approves Mounjaro, Tezspire, Fintepla, Label Expansions for Rinvoq/Skyrizi, Keytruda, and More
September 27, 2022
- Ohara’s High-Need Pediatric Cancer Drug in Limbo 2 Years after Approval due to GMP Issue
February 15, 2019
REGULATORY
- MOF Panel Pushes for Full Drug Price Revision in FY2027: Budget Proposal
November 20, 2026
- Mumps Shots Gain Strong Backing as Japan Weighs FY2027 NIP Priorities
November 20, 2026
- Lilly’s Oral GLP-1 Obesity Drug Heads to Dec. 2 Panel Review, Eyes Japan First
November 19, 2026
- Pharma Prods LDP to Rethink CEA Expansion, Project Team to Compile Proposal
November 19, 2026
- First Pralia Biosimilars Inching Closer to Japan Approval, 5 Products Lined Up
November 19, 2026





